Across Europe, the investment industry is preparing for the introduction of a revised Markets in Financial Instruments Directive (MiFID II) on 3 January 2018.
The biggest change under the new rules will be the requirement for fund management companies to explain clearly to their investors how much of their money is spent on research. This will inevitably impact how companies in the healthcare sector communicate with investors.
The question facing both sides is not only how to value investment research, but who will ultimately pay for it? Will smaller companies still see the same level of investor access and research?
Listen to learn more about these new regulations, the direct impact for investors and biotech companies, and advice on how to proceed.
Speakers:
Amber Fennell, Partner and Co-Founder, Consilium
Charlotte Hill, Partner, Covington
Liz Kelin, Chief Executive Officer, Klein-Edmonds Associates
Dr Martin Turner, Policy and Projects Manager, BIA
